FDA Approves First Biosimilars Interchangeable with Simponi and Simponi Aria

The U.S. Food and Drug Administration (FDA) has approved Immgolis and Immgolis Intri as the first biosimilars interchangeable with Johnson & Johnson's Simponi and Simponi Aria. These biosimilars treat patients with rheumatoid arthritis and ulcerative colitis and are expected to be available in the fourth quarter of this year.